Vivreon Biosciences
We are leveraging our therapeutic discovery platform to create transformative new pharmaceutical companies. Our candidate therapies defend healthy tissue by targeting a central regulator of immune function.
Neuroinflammation is an important contributor to neurodegenerative disease progression, and ongoing neuroinflammation can be visualized in the brains of persons suffering from neurodegenerative diseases. Brain cells called microglia are the source of inflammation in these diseases, and mutations in microglia increase the risk of developing brain disease. Vivreon Neurosciences has discovered a potent lead series of candidate neuroprotective therapeutic drugs that enter the brain and interfere with chronic neurodegenerative microgliosis.
Vivreon Neurosciences
Founding Team
Contact Us
Send
This field is required.
Thank You!
The form has been successfully sent.
This field is required.
This field is required.
This field is required.
This field is required.
milton@vivreonbiosciences.com
3210 Merryfield Row, San Diego, CA 92121
Vivreon Gastrosciences
Inflammatory bowel diseases (IBD) affect more than 1 million people in the United States, with these numbers increasing every year. A large proportion of patients do not respond to current therapies, and there is considerable need to develop improved therapies for IBD patients. Vivreon Gastrosciences was founded to develop an alternative approach to completely and specifically suppress gastrointestinal inflammation.
Vivreon Neurosciences
Neuroinflammation is an important contributor to neurodegenerative disease progression, and ongoing neuroinflammation can be visualized in the brains of persons suffering from neurodegenerative diseases. Brain cells called microglia are the source of inflammation in these diseases, and mutations in microglia increase the risk of developing brain disease. Vivreon Neurosciences has discovered a potent lead series of candidate neuroprotective therapeutic drugs that enter the brain and interfere with chronic neurodegenerative microgliosis.
Vivreon Gastrosciences
Inflammatory bowel diseases (IBD) affect more than 1 million people in the United States, with these numbers increasing every year. A large proportion of patients do not respond to current therapies, and there is considerable need to develop improved therapies for IBD patients. Vivreon Gastrosciences was founded to develop an alternative approach to completely and specifically suppress gastrointestinal inflammation.
Vivreon Biosciences
Oral Immune Therapeutics